Table 3.
MCS and PCS summary scores for DR-TB patients and those enrolled in the comparison groups
| Mental component summary (MCS) | Physical component summary (PCS) | |||
|---|---|---|---|---|
| SF-36 scale$ (Norm-based scale) | Mean | SD | Mean | SD |
| DR-TB (all patients; n = 149) | 38.3 | 12.9 | 50.4 | 9.1 |
| Patient-reported adverse event | ||||
| No adverse event | 42.2 | 13.0 | 52.8 | 8.2 |
| Patient-reported adverse event | 32.1 | 9.9 | 46.5 | 9.1 |
| HIV status | ||||
| HIV negative (n = 27) | 41.4 | 11.6 | 50.9 | 8.7 |
| HIV positive on ART (n = 94) | 38.7 | 12.9 | 51.2 | 8.5 |
| HIV positive not on ART (n = 22) | 34.5 | 13.9 | 46.7 | 10.7 |
| HIV status unknown (n = 6) | 32.7 | 12.5 | 49.0 | 11.6 |
| Duration of DR-TB treatment | ||||
| ≤ 6 months (n = 66) | 31.9 | 11.3 | 48.5 | 9.9 |
| > 6 months (n = 83) | 42.9 | 12.0 | 52.6 | 8.0 |
| DR-TB regimen | ||||
| Standard regimen (long- and short-course) (n = 107) | 37.9 | 13.4 | 51.1 | 8.9 |
| Did not report an AE | 41.4 | 13.6 | 53.2 | 8.2 |
| Self-reported AE | 31.4 | 10.4 | 47.1 | 8.8 |
| Individualized regimen (long- and short-course) (n = 42) | 39.3 | 11.6 | 48.7 | 9.4 |
| Did not report an AE | 45.1 | 10.8 | 51.7 | 8.3 |
| Self-reported AE | 33.4 | 9.3 | 45.6 | 9.7 |
| Comparison groups | ||||
| HIV positive on ART with DS-TB (n = 18) | 44.4 | 15.7 | 48.5 | 9.6 |
| HIV positive on ART no TB (n = 50) | 43.3 | 11.5 | 54.8 | 7.3 |
| Healthy Adultsa (n = 40) | 50.3 | 10.3 | 57.6 | 5.1 |
aFrom published data (van Aswegen et al., 2011)
$Using the 36-Item Medical Outcomes Short Form Health Survey (SF-36)